Pylum Biosciences focuses on developing innovative antibacterial technologies, particularly through their Avidocin™ and Purocin™ protein platforms. Avidocin proteins are engineered to specifically target harmful bacteria while preserving beneficial microbiota, utilizing a mechanism that allows them to bind to unique surface molecules on the target bacteria. This precision minimizes collateral damage to non-target bacteria, making Avidocin proteins effective against drug-resistant strains without triggering toxin release. Their design incorporates only normal amino acids, ensuring biodegradability and safety for the surrounding microbiome, which is crucial for maintaining gut health.

Similarly, Purocin proteins share the targeted approach of Avidocin proteins, binding to specific bacteria and employing a unique mechanism to kill them. This specificity allows Purocin therapeutics to effectively combat pathogenic bacteria, including those responsible for foodborne illnesses like E. coli, Salmonella, and Listeria, without harming beneficial bacteria. Pylum's commitment to developing these proteins aims to address the growing issue of antibiotic resistance and enhance food safety, providing a promising alternative to broad-spectrum antibiotics and chemical treatments.

United States

Pylum is engineeringbacteriocinsand pyocins to target a variety ofpathogenicbacteria including E. coli, and K pneumoniae.Pyocins are similar to phage tail-like protein complexes and have bactericidal activity against strains ofPseudomonas.

Pylum Biosciences

Company Details